White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
KING OF PRUSSIA, Pa., April 26, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 42nd Annual Healthcare Conference hosted by Deutsche Bank Securities on Wednesday, May 3, 2017, at 2:50 p.m. EDT in Boston.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection), currently in Phase 3 development for the management of moderate-to-severe acute pain. Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
